PMID- 27156124
OWN - NLM
STAT- MEDLINE
DCOM- 20170627
LR  - 20180928
IS  - 1097-6760 (Electronic)
IS  - 0196-0644 (Linking)
VI  - 69
IP  - 1
DP  - 2017 Jan
TI  - Acute Toxicity Associated With the Recreational Use of the Novel Psychoactive 
      Benzofuran N-methyl-5-(2 aminopropyl)benzofuran.
PG  - 79-82
LID - S0196-0644(16)30003-8 [pii]
LID - 10.1016/j.annemergmed.2016.03.042 [doi]
AB  - N-methyl-5-(2 aminopropyl)benzofuran (5-MAPB) is a novel psychoactive benzofuran, 
      created by N-methylation of 5-(2-aminopropyl)benzofuran (5-APB), which shares 
      structural features with methylenedioxymethamphetamine (MDMA). To our knowledge, 
      no case of 5-MAPB-related toxicity has been published in the scientific 
      literature. We report a case of oral 5-MAPB exposure confirmed by liquid 
      chromatography-tandem mass spectrometry in a 24-year-old previously healthy white 
      man. Observed symptoms and signs such as paleness, cold and clammy skin, 
      hypertension, elevated high-sensitive troponin T level, tachycardia, ECG change, 
      diaphoresis, mild hyperthermia, mydriasis, tremor, hyperreflexia, clonus, 
      agitation, disorientation, hallucinations, convulsions, reduced level of 
      consciousness, and creatine kinase level elevation (305 IU/L) were compatible 
      with undesired effects related to 5-APB or MDMA exposure. Signs and symptoms 
      resolved substantially within 14 hours with aggressive symptomatic treatment, 
      including sedation with benzodiazepines, external cooling, analgesia and sedation 
      with fentanyl-propofol, and treatment with urapidil, an alpha-receptor-blocking 
      agent. 5-MAPB showed first-order elimination kinetics with a half-life of 6.5 
      hours, comparable to the half-life of MDMA. According to the chemical structure, 
      this case report, and users' Web reports, 5-MAPB appears to have an acute 
      toxicity profile similar to that of 5-APB and MDMA, with marked vasoconstrictor 
      effect.
CI  - Copyright (c) 2016 American College of Emergency Physicians. Published by Elsevier 
      Inc. All rights reserved.
FAU - Hofer, Katharina E
AU  - Hofer KE
AD  - National Poisons Centre, Tox Info Suisse, Associated Institute of the University 
      of Zurich, Zurich, Switzerland. Electronic address: katharina.hofer@toxinfo.ch.
FAU - Faber, Katrin
AU  - Faber K
AD  - National Poisons Centre, Tox Info Suisse, Associated Institute of the University 
      of Zurich, Zurich, Switzerland.
FAU - Muller, Daniel M
AU  - Muller DM
AD  - Institute for Clinical Chemistry, University Hospital Zurich, Zurich, 
      Switzerland.
FAU - Hauffe, Till
AU  - Hauffe T
AD  - Division of Medical Intensive Care Unit, University Hospital Zurich, Zurich, 
      Switzerland.
FAU - Wenger, Urs
AU  - Wenger U
AD  - Division of Medical Intensive Care Unit, University Hospital Zurich, Zurich, 
      Switzerland.
FAU - Kupferschmidt, Hugo
AU  - Kupferschmidt H
AD  - National Poisons Centre, Tox Info Suisse, Associated Institute of the University 
      of Zurich, Zurich, Switzerland.
FAU - Rauber-Luthy, Christine
AU  - Rauber-Luthy C
AD  - National Poisons Centre, Tox Info Suisse, Associated Institute of the University 
      of Zurich, Zurich, Switzerland.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20160504
PL  - United States
TA  - Ann Emerg Med
JT  - Annals of emergency medicine
JID - 8002646
RN  - 0 (Benzofurans)
RN  - 0 (Designer Drugs)
RN  - 0 (N-methyl-5-(2 aminopropyl)benzofuran)
RN  - 0 (Psychotropic Drugs)
RN  - 44RAL3456C (Methamphetamine)
SB  - IM
MH  - Akathisia, Drug-Induced/etiology
MH  - Benzofurans/*toxicity
MH  - Designer Drugs/*toxicity
MH  - Glasgow Coma Scale
MH  - Hallucinations/chemically induced
MH  - Humans
MH  - Male
MH  - Methamphetamine/*analogs & derivatives/toxicity
MH  - Psychotropic Drugs/*toxicity
MH  - Young Adult
EDAT- 2016/05/09 06:00
MHDA- 2017/06/28 06:00
CRDT- 2016/05/09 06:00
PHST- 2016/02/18 00:00 [received]
PHST- 2016/05/09 06:00 [pubmed]
PHST- 2017/06/28 06:00 [medline]
PHST- 2016/05/09 06:00 [entrez]
AID - S0196-0644(16)30003-8 [pii]
AID - 10.1016/j.annemergmed.2016.03.042 [doi]
PST - ppublish
SO  - Ann Emerg Med. 2017 Jan;69(1):79-82. doi: 10.1016/j.annemergmed.2016.03.042. Epub 
      2016 May 4.